Technology area: Biotechnology & Pharmaceuticals
10 pending office actions • 9 art units • 10 examiners • 0 of 10 (0%) have an AI response strategy ready • 13 patents granted in the last 365 days
Antecip Bioventures Ii LLC maintains a company patent portfolio in the Biotechnology & Pharmaceuticals technology area. The portfolio currently has 13 pending office actions. These actions are handled by 13 distinct examiners, meaning each pending action is being reviewed by a different examiner. Prosecution work is spread across 9 distinct art units, reflecting the technical breadth of the company's biotechnology innovations.
WEDDINGTON, KEVIN E is the busiest examiner, currently overseeing 1 busiest examiner pending office action. This matching number between 13 pending office actions and 13 distinct examiners indicates a highly decentralized prosecution effort for the company. The involvement of 9 distinct art units further underscores the breadth of the company's current examination landscape. WEDDINGTON, KEVIN E handles 1 busiest examiner pending office action, which is the same number of actions assigned to every other examiner in this portfolio.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (10%) |
| §102 only | 1 (10%) |
| §112 only | 1 (10%) |
| Double-patenting only | 2 (20%) |
| Double-patenting + other | 5 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WEDDINGTON, KEVIN E | 1 | 75.3% | +9.8% |
| INAM, SAHAR | 1 | 100.0% | +0.0% |
| MOU, LIYUAN | 1 | 43.8% | +59.9% |
| YOUNG, MICAH PAUL | 1 | 55.2% | +30.0% |
| KWON, JOHN SEUNGJAI | 1 | 44.9% | +20.2% |
| STEVENS, MARK V | 1 | 65.5% | +41.6% |
| KIM, SEONG JONG | 1 | 25.0% | +0.0% |
| HAVLIN, ROBERT H | 1 | 51.3% | +28.3% |
| VALENROD, YEVGENY | 1 | 72.5% | +25.1% |
| HUTTER, GILLIAN A | 1 | 54.5% | +46.0% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19464471 | COMPOUNDS AND COMBINATIONS THEREOF FOR TREATING NEUROLOGICAL AND PSYCHIATRIC CONDITIONS | INAM, SAHAR | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18923576 | TREATMENT OF DEPRESSION | KIM, SEONG JONG | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18061091 | BUPROPION AS A MODULATOR OF DRUG ACTIVITY | VALENROD, YEVGENY | 22d |
| 19219972 | BUPROPION AS A MODULATOR OF DRUG ACTIVITY | MOU, LIYUAN | — |
| 18988447 | BUPROPION DOSAGE FORMS WITH REDUCED FOOD AND ALCOHOL DOSING EFFECTS | YOUNG, MICAH PAUL | — |
| 18986390 | TREATMENT OF POOR METABOLIZERS OF DEXTROMETHORPHAN WITH A COMBINATION OF BUPROPION AND DEXTROMETHORPHAN | KWON, JOHN SEUNGJAI | — |
| 18984644 | PHARMACEUTICAL COMPOSITIONS COMPRISING BUPROPION AND CYSTEINE | STEVENS, MARK V | — |
| 18435115 | METHOD OF MAINTAINING REMISSION OF DEPRESSIVE SYMPTOMS | HAVLIN, ROBERT H | — |
| 17937948 | COMPOSITIONS AND METHODS COMPRISING CELECOXIB OR RELATED COMPOUNDS AND DEXTROMETHORPHAN | HUTTER, GILLIAN A | — |
| Art Unit | Apps |
|---|---|
| 1629 | 2 |
| 1622 | 1 |
| 1618 | 1 |
| 1615 | 1 |
| 1613 | 1 |
| 1621 | 1 |
| 1626 | 1 |
| 1628 | 1 |
| 1625 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19684927 | BUPROPION AS A MODULATOR OF DRUG ACTIVITY | WEDDINGTON, KEVIN E | 1629 | §112 | Non-Final OA | — | Pending | May 21, 2026 |
| 19464471 | COMPOUNDS AND COMBINATIONS THEREOF FOR TREATING NEUROLOGICAL AND PSYCHIATRIC CONDITIONS | INAM, SAHAR | 1622 | §112DP | Non-Final OA | — | Pending | Jan 29, 2026 |
| 19219972 | BUPROPION AS A MODULATOR OF DRUG ACTIVITY | MOU, LIYUAN | 1629 | §103§112DP | Non-Final OA | — | Pending | May 27, 2025 |
| 18988447 | BUPROPION DOSAGE FORMS WITH REDUCED FOOD AND ALCOHOL DOSING EFFECTS | YOUNG, MICAH PAUL | 1618 | §102§103DP | Non-Final OA | — | Pending | Dec 19, 2024 |
| 18986390 | TREATMENT OF POOR METABOLIZERS OF DEXTROMETHORPHAN WITH A COMBINATION OF BUPROPION AND DEXTROMETHORPHAN | KWON, JOHN SEUNGJAI | 1615 | §103DP | Non-Final OA | — | Pending | Dec 18, 2024 |
| 18984644 | PHARMACEUTICAL COMPOSITIONS COMPRISING BUPROPION AND CYSTEINE | STEVENS, MARK V | 1613 | DP | Non-Final OA | — | Pending | Dec 17, 2024 |
| 18923576 | TREATMENT OF DEPRESSION | KIM, SEONG JONG | 1621 | §102§103DP | Non-Final OA | — | Pending | Oct 22, 2024 |
| 18435115 | METHOD OF MAINTAINING REMISSION OF DEPRESSIVE SYMPTOMS | HAVLIN, ROBERT H | 1626 | §102Other | Final Rejection | — | Pending | Feb 07, 2024 |
| 18061091 | BUPROPION AS A MODULATOR OF DRUG ACTIVITY | VALENROD, YEVGENY | 1628 | DP | Final Rejection | 22d | Pending | Dec 02, 2022 |
| 17937948 | COMPOSITIONS AND METHODS COMPRISING CELECOXIB OR RELATED COMPOUNDS AND DEXTROMETHORPHAN | HUTTER, GILLIAN A | 1625 | §103 | Non-Final OA | — | Pending | Oct 04, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAntecip Bioventures Ii LLC has 10 pending office actions as of October 2026, spread across 9 art units and 10 examiners.
Kevin E Weddington has the most, with 1 of Antecip Bioventures Ii LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
